|
AnnKatrin Petersen-Jappelli M.D. M.A. Vice President Clinical Development. Dr. Petersen joined us in May 2006 to lead the clinical development team. Prior to joining US Dr. Petersen was the Clinical Development Leader and Strategist Medical Sciences for Hepatitis C and several other exploratory antiviral compounds at Pfizer Inc. In this role she was also a member of the in-licensing due diligence team for anti-infectives. Dr. Petersen joined Agouron Pharmaceuticals Inc (acquired by Pfizer in 2000) in 1996 to become Director of International Clinical Development and Infectious Diseases. At Agouron/Pfizer she was responsible for the phase I - IV clinical development of Viracept (nelfinavir mesylate) for the treatment of HIV infection including filing the NDA and subsequent sNDAs for alternative dosing and pediatric indications. Prior to joining Agouron/Pfizer Dr. Petersen spent close to a decade with other leading international biotechnology and pharmaceutical companies including Sandoz (Novartis) in Switzerland and Cytel in California. She has been responsible for managing the clinical development for several NDA-enabled programs at these companies including Sandimmune (cyclosporine) for Rheumatoid Arthritis and Psoriasis. She received a Master of Economics (1978) and her M.D. degree (1985) from the Université of Lausanne in Switzerland and spent several years working in Internal Medicine before joining the Pharmaceutical Industry. | 